Functional imaging-guided radiotherapy dose escalation in rectal adenocarcinoma: a feasibility study

Not Applicable

Recruiting

• Conditions: Rectal cancer; Cancer - Bowel - Back passage (rectum) or large bowel (colon)

• Registration Number: ACTRN12620000757910
• Lead Sponsor: Dr Myo Min

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-23
• Last Update Posted: 12 September 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Able to give informed consent
- Histologically-proven primary rectal adenocarcinoma within 0-10cm of anorectal junction on MRI or enteroscopy (T3, T4 or node positive disease with no evidence of metastatic spread (M0) on staging CT-chest/abdomen/pelvis (i.e. stage II/III disease))
- Patient undergoing curative intent neoadjuvant radiotherapy +/- chemotherapy
-- Neoadjuvant radiotherapy must be first component of neoadjuvant therapy (i.e. no induction course)
-- Concurrent chemotherapy can include capecitabine or fluorouracil

Exclusion Criteria

- Contraindication to MRI studies (e.g. significant claustrophobia, incompatible pacemaker/implantable defibrillator, implanted metals)
- Patients receiving total neoadjuvant chemotherapy
- Significant imaging artefact precluding accurate MRI-guided radiotherapy planning (bilateral hip replacement etc.)
- Previous radiotherapy to pelvis
- Other malignancy conferring life expectancy of less than 3 years
- Pregnancy
- Active inflammatory bowel disease
- Prior diagnosis of connective tissue disorder

Study & Design

• Study Type: Interventional
• Study Design: Not specified